(Yicai Global) Jan. 27 -- Shares of CanSino Biologics jumped as a single-dose Covid-19 vaccine made by the Chinese firm in Shanghai came on the market today. It is the first Covid jab to be mass produced in the city.

CanSino [SHA: 688185] ended 4.2 percent higher in Shanghai today at CNY264.88 (USD41.60), while its Hong Kong-traded shares [HKG: 6185] declined 3.3 percent to HKD130 (USD16.69).

The recombinant vaccine, named Convidecia, was jointly developed by a team led by Chen Wei, an academician of the Chinese Academy of Engineering, and Tianjin-based CanSino. Approved last February, the vaccine is the sole single-dose inoculation among the seven novel coronavirus jabs authorized for use in China.

The first batch of Shanghai-made Convidecia was produced at a new factory, jointly developed by CanSino and Shanghai Pharmaceuticals, in Baoshan district. Completed and given a vaccine production permit in December, it can make 200 million shots a year.

Editor: Peter Thomas